How Modified RNA Tricks Cells Into Making Proteins Without Triggering Attacks
A breakthrough method for using modified RNA to deliver instructions to cells without causing the body to reject the treatment as a foreign invader.
Original patent title: “RNA containing modified nucleosides and methods of use thereof”
A breakthrough method for using modified RNA to deliver instructions to cells without causing the body to reject the treatment as a foreign invader. Granted to University of Pennsylvania Penn in 2012 with 22 claims and 322 forward citations, and it is now in the public domain.
Coverage
What does this patent actually cover?
This patent describes a way to make synthetic RNA molecules that look and act like natural RNA so the body's immune system doesn't attack them. By replacing the standard building block uridine with a modified version called pseudouridine, the RNA avoids triggering the cell's internal alarm systems, such as Toll-like receptors. This allows the cell to read the RNA instructions and produce a specific protein, like erythropoietin, without the cell shutting down or releasing inflammatory cytokines. The method includes synthesizing this RNA in a lab and delivering it to cells, often inside protective lipid nanoparticles.
The gap
What does this patent NOT cover?
- Does not cover naturally occurring RNA found in the body.
- Does not cover unmodified RNA that triggers a standard immune response.
- Does not cover DNA-based gene therapy or viral vector delivery systems that do not use the specified modified RNA.
- Does not claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → the specific protein being encoded, only the method of using modified RNA to induce its production.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The inventors realized that the immune system's hostility toward synthetic RNA wasn't a bug, but a feature—it was detecting the lack of specific chemical modifications found in natural RNA. By simply swapping one building block, they turned a 'foreign' signal into a 'self' signal.
The Patent Drawing
Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Pfizer-BioNTech COVID-19 vaccine
Moderna COVID-19 vaccine
Experimental mRNA cancer vaccines
Why it matters
The bigger picture
This technology is the foundation for modern mRNA vaccines, including those used against COVID-19. Before this discovery by Katalin Kariko and Drew Weissman, synthetic RNA was largely ignored by the medical community because it was too inflammatory to be useful as a therapy. It effectively unlocked the potential of RNA as a programmable medicine.
Filed
August 21, 2006
Granted
October 2, 2012
Market context
Who's building on this
Companies in this space
Major pharmaceutical companies like BioNTech and Moderna have built their entire platforms on this foundational intellectual property. The University of Pennsylvania holds the patent, which has been licensed out to enable a massive wave of mRNA-based therapeutic research.
Market impact
This patent enabled the creation of an entirely new class of drugs: mRNA therapeutics. It moved RNA from a laboratory curiosity to a viable, scalable commercial product, fundamentally changing how we approach vaccine development and protein replacement therapies.
Claim 1 — Plain English
What this patent covers
This patent describes a way to make synthetic RNA molecules that look and act like natural RNA so the body's immune system doesn't attack them. By replacing the standard building block uridine with a modified version called pseudouridine, the RNA avoids triggering the cell's internal alarm systems, such as Toll-like receptors. This allows the cell to read the RNA instructions and produce a specific protein, like erythropoietin, without the cell shutting down or releasing inflammatory cytokines. The method includes synthesizing this RNA in a lab and delivering it to cells, often inside protective lipid nanoparticles.
The clever bit
The inventors realized that the immune system's hostility toward synthetic RNA wasn't a bug, but a feature—it was detecting the lack of specific chemical modifications found in natural RNA. By simply swapping one building block, they turned a 'foreign' signal into a 'self' signal.
What it does not cover
- Does not cover naturally occurring RNA found in the body.
- Does not cover unmodified RNA that triggers a standard immune response.
- Does not cover DNA-based gene therapy or viral vector delivery systems that do not use the specified modified RNA.
- Does not claim the specific protein being encoded, only the method of using modified RNA to induce its production.
Patent timeline
Application submitted to the patent office
Application published, typically 18 months after filing
Patent officially issued
Patent enters public domain
PatentBrief Score
Impact Score
High impact
Citation count
40/40
Highly cited
Claim breadth
15/20
Broad claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →
Recency
5/20
Granted 10–20 years ago
Assignee scale
20/20
Major company or institution
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$146K – $468K
Midpoint $293K · expired or expiring · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Patent Claims
0 independent claims · 1 dependent
Claims are the legal boundaries of the patent. An independent claim stands alone. A dependent claim adds limitations to its parent, narrowing — but not broadening — the scope.
The original legal language
Original claims
22 claims as filed with the patent office.
Concepts involved
Citations
Patent lineage
Cite this patent
Weissman, D., & Kariko, K. (2012). How Modified RNA Tricks Cells Into Making Proteins Without Triggering Attacks (U.S. Patent No. 8,278,036). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/8278036/rna-containing-modified-nucleosides-and-methods-of-use-thereof
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US8278036"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
Semantically similar
You might also find these interesting
US 10702600 · 2020 · ModernaTx Inc
How Moderna's mRNA Vaccine Technology Targets Betacoronaviruses
US 10113167 · 2018 · Universitaet Wien
How CRISPR-Cas9 Uses RNA to Edit DNA
US 20160166668 · Curevac AG
How an mRNA Vaccine Targets Prostate Cancer with Six Antigens
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does How Modified RNA Tricks Cells Into Making Proteins Without Triggering Attacks cover?
A breakthrough method for using modified RNA to deliver instructions to cells without causing the body to reject the treatment as a foreign invader.
Who owns patent US 8278036?
University of Pennsylvania Penn owns this patent, granted in 2012.
When does this patent expire?
This patent is expected to expire on August 21, 2026, when the invention enters the public domain.
What is patent US 8278036 cited by?
This patent has been cited by 322 later patents that build on its ideas.
What problem does this patent solve?
This technology is the foundation for modern mRNA vaccines, including those used against COVID-19. Before this discovery by Katalin Kariko and Drew Weissman, synthetic RNA was largely ignored by the medical community because it was too inflammatory to be useful as a therapy. It effectively unlocked the potential of RNA as a programmable medicine.
What does this patent NOT cover?
Does not cover naturally occurring RNA found in the body.
Related reading
Same assignee
More from University of Pennsylvania Penn
Patent monitoring